Fresenius Medical Care Overhauls China Strategy to Focus on Innovation

The strategic pivot includes a leadership shakeup with the appointment of Rex Liu as General Manager. Moving forward, the German healthcare giant will concentrate its resources on advanced equipment such as the 5008S CAREsystem and the multiFiltratePRO. CEO Helen Giza emphasized that the realignment is designed to maximize value in a market where demand for chronic kidney disease treatments continues to rise.

To facilitate this transition, the company expects to incur one-time charges of approximately €110 million in the third quarter of 2026. These costs stem primarily from asset impairments and the termination of legacy production lines. Despite the restructuring, leadership maintains that the move will not significantly alter the long-term revenue outlook for its Chinese operations, as the company leans further into its local manufacturing and design capabilities.